What is Gilead Sciences 5-Year EBITDA Growth Rate?
Gilead Sciences's EBITDA per Share for the
three
months ended in Dec. 2023 was $2.07.
During the past 12 months, Gilead Sciences's average EBITDA Per Share Growth Rate was 18.90% per year.
During the past 3 years, the average EBITDA Per Share Growth Rate was 36.60% per year.
During the past 5 years, the average EBITDA Per Share Growth Rate was 5.30% per year.
During the past 10 years, the average EBITDA Per Share Growth Rate was -1.20% per year.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EBITDA per share growth rate.
During the past 13 years, the highest 3-Year average EBITDA Per Share Growth Rate of Gilead Sciences was 118.30% per year. The lowest was -51.30% per year. And the median was 7.00% per year.
Competitive Comparison of Gilead Sciences's 5-Year EBITDA Growth Rate
For the Drug Manufacturers - General subindustry, Gilead Sciences's 5-Year EBITDA Growth Rate, along with its competitors' market caps and 5-Year EBITDA Growth Rate data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Gilead Sciences's 5-Year EBITDA Growth Rate Distribution in the Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Gilead Sciences's 5-Year EBITDA Growth Rate distribution charts can be found below:
* The bar in red indicates where Gilead Sciences's 5-Year EBITDA Growth Rate falls into.
This is the 5-year average growth rate of EBITDA per Share. The growth rate is calculated with least square regression.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EBITDA per share growth rate.
EBITDA per Share is the amount of Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) per outstanding share of the company's stock.
Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) is what the company earns before it expenses interest, taxes, depreciation and amortization.
5-Year EBITDA Growth Rate gives an overview of the company's growth in operating profitability and is an important factor used in calculating Peter Lynch Fair Value.
Gilead Sciences 5-Year EBITDA Growth Rate Related Terms
Thank you for viewing the detailed overview of Gilead Sciences's 5-Year EBITDA Growth Rate provided by GuruFocus.com. Please click on the following links to see related term pages.
Gilead Sciences (Gilead Sciences) Business Description
Gilead Sciences develops and markets therapies to treat life-threatening infectious diseases, with the core of its portfolio focused on HIV and hepatitis B and C. The acquisitions of Corus Pharma, Myogen, CV Therapeutics, Arresto Biosciences, and Calistoga have broadened this focus to include pulmonary and cardiovascular diseases and cancer. Gilead's acquisition of Pharmasset brought rights to hepatitis C drug Sovaldi, which is also part of combination drug Harvoni, and the Kite, Forty Seven, and Immunomedics acquisitions boost Gilead's exposure to cell therapy and noncell therapy in oncology.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
GILD has been successfully added to your